Summary
Benazepril has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Stroke (Ischaemic / Cerebrovascular Disease) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Stroke (Ischaemic / Cerebrovascular Disease). ClinicalTrials.gov lists 3 registered trials linking Benazepril to Stroke (Ischaemic / Cerebrovascular Disease): 2 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT05670028). The largest enrolment is 4000 participants (NCT00664846). Registration activity spans 2008 to 2023. The literature layer holds 2 publications for this pair: 2 clinical trial publications. Publication years run from 2007 to 2015. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Ischemic Stroke ranks 577 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous early neurological improvement in 10-20% within 24 hours of ischaemic stroke without intervention; functional independence at 3 months in only 40-50% without revascularisation; 15% 30-day mortality untreated.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 31.0 (trials 7.0, literature 4.0, tier 15, approved bonus 5.0) |
| Registered trials | 3 total: 0 recruiting, 0 active / not yet recruiting, 2 completed, 1 other |
| Linked publications | 2 (2 clinical trial publications) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | inhibitor |
| Data sources | DGIdb |
| Linked via biomarker / target | ACE |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT05670028 | Cerebral Autoregulation Guiding Blood Pressure Management After Revascularization 2023 | status unknown | Phase 2 | 100 |
| NCT00691314 | Efficacy and Safety of Stent Implantation in Symptomatic Extra- and Intracranial Artery Stenosis 2008 | completed | Not applicable | 300 |
| NCT00664846 | Standard Medical Management in Secondary Prevention of Ischemic Stroke in China 2008 | completed | Not applicable | 4,000 |
Published literature
- Clinical trial publication Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trialSkoglund PH, Svensson P, Asp J et al. · Journal of clinical hypertension (Greenwich, Conn.) · 2015 · PMID 25529596
- Clinical trial publication Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular riskWeber MA, Bakris GL, Dahlöf B et al. · Blood pressure · 2007 · PMID 17453747
Mechanism and notes
Recorded mechanism or class: inhibitor.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ACE. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Benazepril approved for Stroke (Ischaemic / Cerebrovascular Disease)?
Benazepril has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Stroke (Ischaemic / Cerebrovascular Disease) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Stroke (Ischaemic / Cerebrovascular Disease). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Benazepril in clinical trials for Stroke (Ischaemic / Cerebrovascular Disease)?
ClinicalTrials.gov lists 3 registered trials linking Benazepril to Stroke (Ischaemic / Cerebrovascular Disease): 2 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT05670028). The largest enrolment is 4000 participants (NCT00664846). Registration activity spans 2008 to 2023.
What does the evidence show for Benazepril in Stroke (Ischaemic / Cerebrovascular Disease)?
Benazepril has 2 completed trials and 2 linked publications for Stroke (Ischaemic / Cerebrovascular Disease). Completed trials may or may not have posted results; follow the NCT links to check. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ACE. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.